Loading...
CanSino Biologics Inc.
CASBF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$4.90
$0.00(0.00%)
CanSino Biologics Inc. (CASBF) Financial Performance & Income Statement Overview
Review CanSino Biologics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
138.97%
↑ 138.97%
Operating Income Growth
80.18%
↑ 80.18%
Net Income Growth
74.45%
↑ 74.45%
Operating Cash Flow Growth
81.58%
↑ 81.58%
Operating Margin
-156.68%
↓ 156.68%
Gross Margin
53.52%
↑ 53.52%
Net Profit Margin
-156.19%
↓ 156.19%
ROE
-14.05%
↓ 14.05%
ROIC
-11.61%
↓ 11.61%
CanSino Biologics Inc. (CASBF) Income Statement & Financial Overview
Review CanSino Biologics Inc.'s (CASBF) income statement with detailed quarterly and annual figures.
Metric | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
---|---|---|---|---|
Revenue | $261.05M | $186.85M | $112.31M | $179.50M |
Cost of Revenue | $54.84M | $75.56M | $46.23M | $116.93M |
Gross Profit | $206.22M | $111.29M | $66.08M | $62.57M |
Gross Profit Ratio | $0.79 | $0.60 | $0.59 | $0.35 |
R&D Expenses | $86.37M | $68.73M | $96.75M | $157.16M |
SG&A Expenses | $117.23M | $109.23M | $90.90M | $247.69M |
Operating Expenses | $199.61M | $184.24M | $195.45M | $585.59M |
Total Costs & Expenses | $254.45M | $259.80M | $241.69M | $702.52M |
Interest Income | $12.53M | $15.36M | $23.43M | $24.86M |
Interest Expense | $14.69M | $18.05M | $14.67M | $18.19M |
Depreciation & Amortization | $11.63M | $56.40M | $60.10M | $67.23M |
EBITDA | $18.23M | $23.20M | -$90.68M | -$455.79M |
EBITDA Ratio | $0.07 | $0.12 | -$0.81 | -$2.54 |
Operating Income | $6.60M | -$72.95M | -$129.37M | -$523.02M |
Operating Income Ratio | $0.03 | -$0.39 | -$1.15 | -$2.91 |
Other Income/Expenses (Net) | -$3.06M | $18.63M | -$32.38M | -$991854.00 |
Income Before Tax | $3.54M | -$51.24M | -$161.75M | -$524.01M |
Income Before Tax Ratio | $0.01 | -$0.27 | -$1.44 | -$2.92 |
Income Tax Expense | $528007.00 | $963812.00 | $8.34M | -$10.29M |
Net Income | $2.96M | -$55.28M | -$170.10M | -$497.70M |
Net Income Ratio | $0.01 | -$0.30 | -$1.51 | -$2.77 |
EPS | $0.01 | -$0.22 | -$0.69 | -$2.01 |
Diluted EPS | $0.01 | -$0.22 | -$0.69 | -$2.01 |
Weighted Avg Shares Outstanding | $247.16M | $247.16M | $247.17M | $247.19M |
Weighted Avg Shares Outstanding (Diluted) | $247.16M | $247.16M | $247.17M | $247.19M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan